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Abstract 
Background: Community-drug distribution point is a care model for stable patients in the community designed 
to make ART delivery more efficient for the health system and provide appropriate support to encourage long-term 
retention of patients. We examined program retention among ART program participants in rural Uganda, which has 
used a community-based distribution model of ART delivery since 2004.
Methods: We analyzed data of all patients >18 years who initiated ART in Jinja, Ugandan site of The AIDS Sup-
port Organization between January 1, 2004 and July 31, 2009. Participants attended clinic or outreach visits every 
2–3 months and had CD4 cell counts measured every 6 months. Retention to care was defined as any patient with 
at least one visit in the 6 months before June 1, 2013. We then identified participants with at least one visit in the 
6 months before June 1, 2013 and examined associations with mortality and lost-to-follow-up (LTFU). Participants 
with >4 years of follow up during August, 2012 to May, 2013 had viral load conducted, since no routine viral load test-
ing was available.
Results: A total of 3345 participants began ART during 2004–2009. The median time on ART in June 2013 was 
5.69 years. A total of 1335 (40 %) were residents of Jinja district and 2005 (60 %) resided in outlying districts. Of these, 
2322 (69 %) were retained in care, 577 (17 %) died, 161 (5 %) transferred out and 285 (9 %) were LTFU. Factors associ-
ated with mortality or LTFU included male gender, [Adjusted Hazard Ratio (AHR) = 1.56; 95 % CI 1.28–1.9], CD4 cell 
count <50 cells/μL (AHR = 4.09; 95 % CI 3.13–5.36) or 50–199 cells/μL (AHR = 1.86; 95 % CI 1.46–2.37); ART initiation 
and WHO stages 3 (AHR = 1.35; 95 % CI 1.1–1.66) or 4 (AHR = 1.74; 95 % CI 1.23–2.45). Residence outside of Jinja 
district was not associated with mortality/LTFU (p value = 0.562). Of 870 participants who had VL tests, 756 (87 %) had 
VLs <50 copies/mL.
Conclusion: Community-based ART distribution systems can effectively mitigate the barriers to program retention 
and result in good rates of virologic suppression.
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Background
Large-scale antiretroviral treatment (ART) programs for 
HIV and AIDS were launched in sub-Saharan Africa in 
2003–2004 with the increases in funding made available 
through the Global Fund Against AIDS, Tuberculosis and 
Malaria and the President’s Emergency Plan for AIDS 
Relief (PEPFAR) [1–3]. From their inception, much atten-
tion was then focused on patients’ day-to-day adherence 
to ART which have generally shown very good results [1, 
3–5].
However, long-term retention of patients in treatment 
programs, a prerequisite for achieving any adherence at 
all has gained more attention in recent years [4]. Most 
large-scale treatment providers have few resources availa-
ble to track missing patients; and patient attrition is often 
not prioritized as a primary outcome and clinical studies 
often focus solely on describing those patients who are 
retained in care. In a study conducted in 17 facilities in 
Uganda, Tanzania and Zambia, loss to follow up ranged 
from an average of 25.9 % at 1 year to 41.9 % at 4 years 
[8]. Other studies have shown that transportation costs, 
absence of treatment partner or lack of family support as 
significant barrier to program retention [6, 7, 12, 16, 24].
In studies with follow-up beyond the first 4  years of 
treatment, LTFU has been shown to vary between 7 % in 
a program in Malawi [6, 10] to 56 % for one program in 
Uganda [7]. In a recent systematic review of participant 
retention in ART programs in Africa, researchers found 
an estimated median retention of care of 64.4  % (range 
57.5–72.1  %) after 3  years after ART initiation among 
39 cohorts with over 225,000 patients in total [8]. LTFU 
was the most common factor for not been retained [13, 
18]. Possible explanations for these variations in patient 
retention include patients having to pay for their medi-
cation, patients accessing care at another facility and 
unreported mortality [6, 10 16]. Additionally, lack of 
transportation and distance from the clinic, financial 
strain, work or child care responsibilities, social issues, 
and feeling that their health was too poor or too good to 
warrant continuing have all been identified as barriers to 
being retained in care [6, 10, 16]. When investigated, the 
proportion of patients LTFU who were then discovered 
to have died ranged from 25 to 50 % [1, 10, 17, 19].
We undertook an analysis of program data at one of 
the TASO centers in Jinja, Uganda to examine program 
retention, LTFU and mortality among clients enrolled 
in the first 5  years of the ART program. Our primary 
interest was in examining whether clients from districts 
which were distant from the TASO centre had the same 
likelihood of being retained in care, as those who resided 
close to the TASO clinic. In a sample of those retained 
in care after 5 years of treatment, we also conducted VL 
testing to measure the prevalence of virologically defined 
treatment failure in a program without access to routine 
VL testing.
Results
A total of 3340 participants began ART during 2004–
2009 and the median time on ART for these individuals 
in June 2013 was 5.7 years (IQR = 4.1–7.2). Of these indi-
viduals, 2379 (71 %) were females, the median age at ART 
initiation was 40 years (IQR = 34–46), and 1618 (55 %) 
of the participants had some primary education as their 
highest level attained. The median CD4 cell count at ini-
tiation was 184 cells/μL (IQR = 95–298). A total of 1335 
(40  %) were residents of Jinja district and 2005 (60  %) 
resided in outlying districts. A total of, 1361 (44 %) of the 
participants began treatment on Nevirapine, Zidovudine 
and Lamivudine, 950 (31 %) began with Niverapine, Sta-
vudine and Lamivudine and 323 (11 %) began with Efa-
virenz, Zidovudine and Lamivudine.
A total of 2317 (69  %) participants had at least one 
recorded clinic or outreach visit recorded between 
November 1, 2012–May 31, 2013. For participants not 
retained in care, 577 (17 %) were known to have died, 161 
(5 %) had transferred out and 285 (9 %) were classified as 
LTFU. The mortality rate was 3.22/100 and the rate LTFU 
was 1.59/100 person years. Table  1 shows the bivariate 
analysis of factors associated with mortality or LTFU. 
Male participants represented a higher proportion of 
those who died or LTFU than those who were retained in 
care 37 vs 25 %, respectively; (p < 0.001). We also found 
that WHO stage at treatment initiation (p < 0.001), CD4 
cell count at initiation (p < 0.001) hemoglobin values at 
ART initiation (p  <  0.001) and occupation (p  =  0.045) 
were higher in those who died or were LTFU. District of 
residence at ART initiation was also unequally distrib-
uted across the four vital status categories (p  <  0.001). 
However, when expressed as row percentages (rather 
than column percentages as in Table  1) the proportion 
retained in care had a fairly narrow range from a low 
67 % in Jinja to a high 73 % in surrounding districts (data 
not shown). Mortality ranged from 14  % in Buikwe to 
20 % in Mayuge and LTFU ranged from 4 % in Mayuge to 
10 % in “other districts”.
In the multivariate Cox proportional hazards analy-
sis of factors associated with time to death or LTFU 
as in Table  1, male gender [adjusted hazard ratio 
(AHR) = 1.56; 95 % CI 1.28–1.9] was significantly asso-
ciated with LTFU or mortality. CD4 cell count <50 
(AHR  =  4.09; 95  % CI. 3.13–5.36) or 50–199 cells/
μL (AHR  =  1.86; 95  % CI 1.46–2.37) at ART initiation 
and WHO stages 3 (AHR =  1.35; 95  % CI 1.1–1.66) or 
4 (AHR  =  1.74; 95  % CI 1.23–2.45) were also associ-
ated with the outcome. Participants who received Sta-
vudine, Lamivudine and Nevirapine, (AHR = 1.38; 95 % 
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CI 1.08–1.76) or atypical ARV regimens (AHR  =  1.41; 
95 % CI 1.00–1.99) also had an increased hazard of mor-
tality/LTFU in comparison to those who began therapy 
with Nevirapine, Zidovudine and Lamivudine. As well, 
the year of ART initiation (AHR =  1.32 per year; 95  % 
CI 1.20–1.46) was significantly associated with mortal-
ity/LTFU. Notably, residence in any of the areas outside 
of Jinja district, again was not associated with mortality/
LTFU in this analysis (p value = 0.562) in comparison to 
those who resided in Jinja.
We conducted HIV viral load testing on 870 clients of 
TASO Jinja who had been on ART for more than 4 years 
and presented for care between June 2012 and August 
2013. Of these, we could link 805 (92.5  %) to the elec-
tronic database records. These individuals had been 
receiving ART for a median of 7.0 (IQR 5.0–8.0) years. 
Table 1 Cox proportional hazards analysis of factors associated with time to mortality or loss to follow up
List of clinical factors Univariate Multivariate
HR (95 % CI) p value HR (95 % CI) p value
Age at ART initiation 0.99 (0.98, 1.00) 0.065 1.00 (0.99, 1.01) 0.720
First ARV regimen
 Nevirapine/zidovudine/lamivudine 1.00 (–) 0.018 1.00 (–) 0.003
 Efavirenz/stavudine/lamivudine 0.64 (0.39, 1.03) 0.87 (0.53, 1.44)
 Efavirenz/zidovudine/lamivudine 0.61 (0.42, 0.89) 0.74 (0.51, 1.09)
 Nevirapine/stavudine/lamivudine 0.91 (0.74, 1.14) 1.38 (1.08, 1.76)
 Other ARV regimen 1.21 (0.86, 1.71) 1.41 (1.00, 1.99)
WHO stage
 Stages 1 and 2 1.00 (–) <0.001 1.00 (–) 0.002
 Stage 3 1.52 (1.24, 1.85) 1.36 (1.1, 1.67)
 Stage 4 1.82 (1.3, 2.56) 1.72 (1.21, 2.43)
CD4 at ART initiation
 ≥200 1.00 (–) <0.001 1.00 (–) <0.001
 50–199 2.21 (1.75, 2.8) 1.86 (1.46, 2.37)
 <50 5.25 (4.07, 6.78) 4.11 (3.13, 5.4)
District of residence at ART initiation
 Jinja 1.00 (−) 0.879 1.00 (–) 0.562
 Buikwe 0.87 (0.65, 1.15) 0.92 (0.69, 1.22)
 Iganga 0.87 (0.65, 1.15) 0.77 (0.58, 1.03)
 Kamuli 0.92 (0.66, 1.28) 0.92 (0.66, 1.28)
 Mayuge 0.95 (0.7, 1.27) 0.95 (0.7, 1.28)
 Other 0.85 (0.55, 1.31) 0.77 (0.5, 1.19)
Education level
 None/preprimary/other 1.00 (–) 0.587 1.00 (–) 0.400
 Higher education 0.89 (0.5, 1.58) 0.73 (0.39, 1.38)
 Some secondary 0.91 (0.67, 1.25) 0.81 (0.58, 1.12)
 Some primary 1.07 (0.82, 1.39) 0.97 (0.74, 1.28)
Gender
 Female 1.00 (–) <0.001 1.00 (–) <0.001
 Male 1.62 (1.34, 1.96) 1.6 (1.3, 1.97)
Occupation
 Peasant 1.00 (–) 0.136 1.00 (–) 0.065
 Casual laborer 1.24 (0.9, 1.72) 1.13 (0.81, 1.58)
 None 1.32 (1.02, 1.71) 1.34 (1.02, 1.74)
 Other 1.15 (0.83, 1.6) 1.13 (0.8, 1.58)
 Paid employee 1.01 (0.7, 1.45) 0.92 (0.61, 1.39)
 Vendor/business person 0.86 (0.63, 1.17) 0.79 (0.57, 1.08)
Year of ART initiation 1.39 (1.29, 1.51) <0.001 1.32 (1.2, 1.46) <0.001
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The similarities and differences in this sample in com-
parison to the entire TASO-Jinja cohort are presented in 
Table  2. Note that this sample included six participants 
who were identified as having transferred out and two 
who were considered LTFU. The sample had more female 
participants (77 vs. 69.2  %; p  <  0.001) had higher CD4 
cell counts at enrollment (97 vs. 69 %; p < 0.001) (74.7 % 
female vs 69.4 %; p < 0.001) (Table 3).
Of these individuals, 753 (87  %) of the patients 
had  >  90  % adherence to therapy based on self-report 
of missed doses. A total of 756 (87  %) participants had 
VLs < 50 copies/mL and 809 (93 %) had VLs <1000 cop-
ies/ml. Table  4 shows the bivariate analysis of factors 
associated with virologic failure, defined as a VL ≥1000 
copies/mL. Patients with VLs ≥1000 copies/mL were 
likely to be older than those with VLs <1000 copies/mL 
(median 45 Vs 42 years; p < 0.003). A lower proportion 
of women had virologic failure (67 vs 77 %), but this was 
only marginally significant (p =  0.083). Those with VLs 
≥1000 copies/mL had lower CD4 cell counts at the time 
of VL testing (median 253 cells/μL) than those with VLs 
<1000 copies/mL (575 cells/μL; p  <  0.001). We found a 
significant association between virologic failure meeting 
the CD4 cell count criteria treatment failure as defined 
by WHO (p  <  0.001). Those with virologic failure were 
also younger than those without (median age 42  vs. 
45  years; p  <  0.001). There were no significant associa-
tions between virologic failure with regimen type, educa-
tion level, or occupation in the bivariate analysis. Logistic 
regression analysis revealed that the most recent CD4 cell 
count [adjusted odds ratio (AOR) = 0.51 per 100 cells/μl; 
95 % CI 0.43–0.60] and age (AOR = 0.96 per year; 95 % 
CI 0.92–0.99) were significantly associated with virologic 
failure as shown in Table  4. We also found that partici-
pants whose initial ART regimen was Nevirapine/Sta-
vudine/Lamivudine had an increased odds of virologic 
failure (AOR = 1.38; 95 % CI 1.08–1.76) in comparison to 
those who started with Nevirapine/Zidovudine/Lamivu-
dine (reference category).
Discussion
This study of over 3000 participants in the TASO ART 
Program in Jinja, Uganda demonstrated that more than 
69  % of patients who initiated ART from 2004 to 2009 
were retained in care after more than 5  years of treat-
ment. This finding demonstrates that high retention rates 
are possible even in rural, resource-limited settings, par-
ticularly when programs are designed to be client-cen-
tered. Not only was retention in care quite high only 9 % 
of participants became LTFU and mortality was relatively 
low at 17 % and among those retained in care 93 %, had a 
VL result of <1000 copies/mL, even without access to VL 
testing for ART monitoring. While some programs have 
reported similar rates of retention [3, 17, 21, 23, 25, 26, 
27, 28], they most often have been reported with study 
populations with shorter duration of follow-up (17, 21 
22, 23, 25, 26] often in the range of 2 years after ART ini-
tiation [1, 16, 20], as opposed to the median of 5 years of 
follow-up in our study. For example, Assefa et al., in the 
study of outcomes of the ART services in the 55 health 
facilities in Ethiopia, reported an average 68 % (95 % CI 
51–85) of patients retained in care after 2 years of follow-
up [1]. The program at TASO, therefore, has retention 
figures which are among the better performing programs 
in the region even over longer follow-up periods.
We also found that, the risk for mortality and LTFU did 
not differ based on the geographic residence of program 
participants. This suggests that community-based distri-
bution systems in use at TASO has effectively mitigated 
the time and cost constraints associated with transporta-
tion to ART clinic sites which have been demonstrated as 
barrier to retaining ART patients in care [3, 7, 31].
Among those retained in care and receiving first-line 
ART, we found a very low prevalence of virologic fail-
ure and very few with detectable VL measurements (i.e. 
≥50 copies/mL) even in the absence of VL monitoring. 
While the new WHO 2013 guidelines for the use of ART 
in resource-limited settings recommend the use of VL 
testing, it is important to note that ART programs with 
only routine CD4 testing and good adherence strate-
gies can achieve excellent outcomes and high rates of 
virologic suppression, even in the absence of such test-
ing. However, it also appears that even the use of these 
clinical tools available at TASO have not been completely 
optimized since, we found 44 individuals (5  %) in our 
sub-study of virologic failure who met criteria for immu-
nologic failure and whom had not yet been switched to 
second-line therapy. The fact that only 19 of the 44 were 
found to have VLs ≥1000 copies/mL, suggests confirm-
ing virologic failure amongst individuals who meet clini-
cal or immunologic criteria for failure may be a more 
useful role for VL testing than screening large numbers 
of participants who are clinically well.
While our mortality rate was fairly low (3.22 per 100 
person-years), in comparison to other studies in Africa 
reporting 5.1 per 100 person-years [6–9, 14] previ-
ous studies have shown that underreporting of mortal-
ity due to LTFU can bias the reporting of mortality, [20, 
22]. However, as LTFU in our study was also low, this 
does not appear to be the explanation for this observa-
tion in our study. Of course, since most mortality on ART 
occurs within the first few months of initiation, it is also 
expected that studies with longer follow-up time will also 
yield lower mortality rates [15, 22, 31].
The rate of LTFU of 1.59 per 100 person-years in our 
cohort is comparable to that observed in the South Africa 
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studies [17], but relatively lower as compared to the rate 
observed in Western Kenya which found, 5.1 per 100 
person-years of observation [31]. The careful design 
and scale up of ART in TASO may have contributed to 
the observed LTFU. This program has grown in size 
dramatically, with our cohort increasing enrolment about 
3-fold from 2004 to 2013.
These findings could be limited because death was 
ascertained by patient record review. Consequently, 
deaths, which occurred at home, might have not been 
Table 2 Comparison of participants in viral load sub-study in 2012 -13 with other participants in Jinja Cohort
N = 3345 Jinja cohort participants
Variable Total N Participants in VL sub-study p value
No (N = 2540) Yes (N = 805)
N (%) N (%)
Clinical outcomes 3345 <0.001
 Survived and retained in care 1525 (60) 797 (99)
 Dead 577 (23) 0 (0)
 Lost to follow-up 283 (11) 2 (0)
 Transferred out 155 (6) 6 (1)
Gender 3345 <0.001
 Female 1757 (69) 623 (77)
 Male 783 (31) 182 (23)
CD4 at ART initiation 3099 <0.001
 <50 429 (18) 55 (7)
 50–199 958 (42) 278 (35)
 ≥200 915 (40) 464 (58)
Hemoglobin count of participant at ARV initiation or clinical visit 2222 0.025
 <8 71 (4) 13 (2)
 ≥8 1574 (96) 564 (98)
WHO stage 2829 0.749
 Stage 1 40 (2) 10 (1)
 Stage 2 992 (47) 359 (49)
 Stage 3 913 (44) 318 (43)
 Stage 4 147 (7) 50 (7)
Occupation 2920 0.384
 Casual labourer 202 (9) 59 (9)
 Paid employee 187 (8) 48 (7)
 Peasant 940 (41) 268 (41)
 Vendor/business person 321 (14) 98 15)
 Other 246 (11) 61 (9)
 None 401 (17) 89 (14)
Education level 2920 0.092
 None/preprimary/other 382 (17) 100 (16)
 Some primary 1294 (56) 324 (52)
 Some secondary 545 (24) 174 (28)
 Higher education 75 (3) 26 (4)
First ARV regimen 3076 0.003
 Efavirenz/Zidovudine/Lamivudine 233 (10) 90 (11)
 Efavirenz/Stavudine/Lamivudine 136 (10) 64 (8)
 Nevirapine/Stavudine/Lamivudine 688 (30) 262 (33)
 Nevirapine/Zidovudine/Lamivudine 1034 (45) 327 (42)
 Other ARV regimen 198 (7) 44 (6)
Year of ART initiation 3345 2006 (2006–2008) 2006 (2005–2007) <0.001
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documented in the patient card. This may underestimate 
the rate of mortality. For this reason we combined LTFU 
with mortality as our outcome. As the data we used for 
this analysis was routinely collected and entered by cli-
nicians as part of providing clinical care, it lacks some 
accuracy and was not complete. This may underestimate 
Table 3 Bivariate analysis of 870 participants with and without viral load <1000 copies/ml
N = 870
Variable Total N Viral load result (copies/mL) p value
<1000 (N = 809) ≥1000 (N = 61)
N (%) N (%)
Gender 870 0.083
 Female 623 (77) 41 (67)
 Male 186 (23) 20 (33)
Most important source of income 870 0.399
 Agricultural farming 254 (31) 16 (26)
 Wage or salaried employment 93 (11) 8 (13)
 Crafts and trade work 54 (7) 2 (3)
 Petty trade in kiosks stalls and hawking 198 (24) 22 (36)
 None 77 (10) 5 (8)
 Other 133 (16) 8 (13)
Education level 869 0.127
 No education (including do not know) 173 (21) 8 (13)
 Some/completed primary 357 (44) 25 (41)
 Some/completed high school/higher education 278 (34) 28 (46)
Current marital status 870 0.186
 Single/separated/divorced/widowed 481 (59) 31 (51)
 Legally married/co habiting 328 (41) 30 (49)
Any evidence of CD4 cell count treatment failure? 867 <0.001
 No 781 (97) 42 (69)
 Yes 25 (3) 19 (31)
Current ARV regimen (first regimen) 870 0.084
 Nevirapine 626 (77) 53 (87)
 Efavirenz 183 (23) 8 (13)
Current ARV regimen (second regimen) 870 0.417
 3TC/ZDV 744 (92) 54 (89)
 FTC/TDF 1 (0) 0 (0)
 3TC/TDF 63 (8) 7 (11)
 3TC/ABC 1 (0) 0 (0)
Frequency taking ARV pills 869 0.826
 Never 517 (64) 37 (61)
 Once a week 54 (7) 5 (8)
 More than once a week but less than a month 54 (7) 3 (5)
 More than a month 183 (23) 16 (26)
 Adherence (frequency missing ARV pills) 869 0.956
 Never or more than a month 700 (87) 53 (87)
 Once a week or more than once a week but less than a month 108 (13) 8 (13)
Alcohol within previous month 870 0.903
 No 739 (91) 56 (92)
 Yes 70 (9) 5 (8)
Age at time of VL test 870 45 (40–50) 42 (37–45) 0.003
Most recent CD4 cell count (cells/mm3) 867 575 (445–757) 253 (118–426) <0.001
Duration on ART (years) 870 7 (6–8) 7 (5–8) 0.775
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or overestimate some outcome of interest. As well some 
variables were extensively missing and we could not 
include them in multivariate analyses. As well, there is 
some possibility of misclassification as we observed six 
patients in the virologic failure sub-study who were clas-
sified as having transferred out of the program and two 
other participants in the sub-study met our criteria of 
LTFU, despite being in care.
Conclusion
Among participants enrolled in an ART program for a 
median of over 5 years, rates of mortality and LTFU were 
very low and did not differ based on the geographic resi-
dence of program participants. This demonstrates that 
community-based distribution systems can effectively 
mitigate the time and cost constraints associated with 
transportation to ART clinic sites. As well, ART pro-
grams which only routine CD4 testing and good adher-
ence strategies can expect good clinical and virologic 
outcomes.
Methods
Study design
We conducted a retrospective cohort analysis of all 
patients >18  years old who initiated ART at the TASO 
service clinic in Jinja. Jinja clinic is one of the eleven 
TASO ART clinics in Uganda which serves clients within 
a radius of 75 km. Between January 2004 and July 2009 
the CD4 count cut off point for ART eligibility increased 
from 200 to 250 cell/ml. The AIDS Support Organization 
(TASO) has the largest non-governmental ART pro-
gram in the country with more than 80,000 individu-
als accessing care and over 65,000 individuals receiving 
ART through 11 service centers, the ART program has 
been designed to accommodate the needs of clients since 
its inception. This has been operationalized in terms of 
providing clients with much more than just clinic visits 
and medications. Several types of program delivery mod-
els have been implemented and revised over the past 
10 years at TASO, including home-based care [11, 30] the 
use of satellite clinics, community drug distribution [29], 
as well as more conventional clinic-based approaches. In 
TASO, patients who are initiated on ART after 6 months 
of ART treatment are evaluated by clinicians and coun-
selors for down referred to Community Drug Distribu-
tion Point (CDDP). A CDDP is a small group of 20–50 
patients who have been on ART for at least 6  months, 
are stable clinically, have disclosed their sero-status to 
a friend or relative and have consented to down referral 
to the community for continued ART refill, monitoring 
by lay workers. The patients themselves identify a place 
within their community where they converge to receive 
their refills, ART reviews and evaluation by TASO coun-
selors (lay workers) and six monthly reviews by TASO 
clinical staff. The group elects a leader who is an expert 
client who then mobilizes and follows up all the patients 
in his/her group for adherence and other counseling 
issues, he is also responsible for up referral of the patients 
to the facility in case of any illness or suspected medica-
tion side effect. In the CDDP, Drug refills are conducted 
Table 4 Univariate and multivariate logistic regression analysis of factors associated with virologic failure
Univariate Multivariate
OR (95 % CI) p value OR (95 % CI) p value
Gender 0.081
 Female 1.00 (–)
 Male 1.65 (0.94, 2.89)
Education level 0.101 0.132
 No education (including do not know) 1.00 (–) 1.00 (–)
 Some/completed Primary 1.47 (0.65, 3.34) 1.51 (0.61, 3.72)
 Some/completed high school/higher education 2.25 (1, 5.04) 2.34 (0.95, 5.76)
Current marital status 0.265
 Single/separated/divorced/widowed 1.00 (–)
 Legally married/co habiting 1.35 (0.8, 2.28)
Current ARV regimen (first regimen) 0.091
 Nevirapine 1.00 (–)
 Efavirenz 0.52 (0.24, 1.11)
Age (in years) 0.95 (0.91, 0.98) 0.003 0.96 (0.92, 0.99) 0.020
Number of child dependents 0.95 (0.88, 1.02) 0.174
Most recent CD4 cell count (per 100 cells/μl) 0.50 (0.42, 0.59) <0.001 0.51 (0.43, 0.6) <0.001
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every 2 to 3 months, with clinical assessments conducted 
at the time of drug refills by health professionals and 
CD4 cell counts performed every 6  months by labora-
tory technician. No routine VL monitoring is performed 
as part of this program. For community-based drug dis-
tribution, ART is provided at the community by trained 
lay workers, who are mostly social workers and teachers 
supervised by Clinical Services Supervisor.
Data collection
In June of 2013, we used the clinical database of TASO 
Jinja, to extract clinical data at enrollment and subse-
quent visits, the data collected included WHO stage, 
baseline CD4, CD4 at subsequent visits, HB, distance to 
the service centre, ART start date and regimen, as well 
as basic socio-demographic information. The database 
also records information on known deaths and patients 
who have transferred out of the program. When neces-
sary, patient charts in use at TASO Jinja were used to 
supplement the information found in the clinical data-
base. Individual consent was not obtained from the study 
participants but the patient records were anonymized 
and de-identified prior to analysis. Additionally, between 
August 2012 and May 2013, we obtained funding to con-
duct viral load (VL) tests for clients who attended the 
clinic or outreach site and who had been on ART for at 
least 4 years, while still on a first-line ART regimen. The 
Participants in this component of the study did provide 
individual written informed consent. The study protocol 
and consent forms were approved by the Research Ethics 
Board of the University of British Columbia, the TASO 
Research Ethics Committee, the Uganda Virus Research 
Institute and the Uganda National Council for Science 
and Technology.
Data analysis
Retention in care was defined by a record of at least 
one clinic visit in the 6 months before June 1, 2013. We 
included factors that determined retention and mortal-
ity among adults enrolled in HIV service delivery mod-
els and conducted bivariate analyse using Kruskal–Wallis 
and Chi square tests using STATA version 16 to compare 
clients who remained active program clients throughout 
the study period, with those who are known to have died 
or who were LTFU. We used Cox Proportional Hazards 
Modeling to determine factors associated with the com-
bined outcome of mortality and LTFU, given that the 
bivariate analysis suggested more similarities between 
participants in these categories than with those retained 
in care or transferred out. District of residence was our 
primary explanatory variables of interest, but we exam-
ined other important co-factors, such as CD4 counts at 
treatment initiation, gender, ethnicity, and other variables 
for potential inclusion in explanatory models. For the 
analysis of virologic failure, we calculated the propor-
tion of individuals with virologic failure defined as ≥1000 
copies/mL. We then conducted a bivariate analysis with 
participants classified on the basis of presence or absence 
of viral failure (defined as a VL of ≥1000 copies/mL) and 
examined factors independently associated with virologic 
failure using multivariate logistic regression.
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